Month: April 2020

RACINE, Wis., April 08, 2020 (GLOBE NEWSWIRE) — Twin Disc, Inc. (NASDAQ: TWIN), provides an update on the actions it is taking in response to the impact of the COVID-19 crisis. “We are taking prudent and aggressive measures to respond to the rapidly evolving COVID-19 crisis as well as the significant reduction in the global oil and gas prices,” stated John H. Batten, Chief Executive Officer.In response to lower demand across many of the company’s global markets, Twin Disc is taking the following temporary actions at its North American operations to reduce costs:Temporary layoff of ten salaried employeesReducing paid hours of certain salaried positions by 25%A 15% reduction in salaries for all remaining full-time employees; 20% for the CEO and COOEstimated annualized savings from salaried payroll actions total $4.1 millionDeferring...

The U.S. FDA approved vaccine is being provided to help protect critical healthcare workers in emergency medical settings from hepatitis B infectionsEMERYVILLE, Calif., April 08, 2020 (GLOBE NEWSWIRE) — Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced it is donating 10,000 doses of HEPLISAV-B adult vaccine to help protect healthcare professionals on the front lines of the COVID-19 response against hepatitis B, a potentially deadly virus that is spread through contact with infected blood and bodily fluids and can live on surfaces for at least seven days.Direct Relief is administering the donation program on behalf of Dynavax.  Interested healthcare providers and facilities throughout the U.S. who are vaccinating surge healthcare...

AUSTIN, Texas, April 08, 2020 (GLOBE NEWSWIRE) — SmallCapVoice.com, Inc. and Nightfood, Inc. (OTCQB: NGTF), the award-winning ice cream company addressing America’s $50 billion-dollar nighttime snacking problem, announced today that the Company is featured in a new audio interview at SmallCapVoice.com, Inc.The interview can be heard at: https://www.smallcapvoice.com/4-2020-interview-nightfood-ngtf/.Nightfood CEO Sean Folkson, called back in to SmallCapVoice.com, Inc. to discuss recent Nightfood developments as the Official Ice Cream of the American Pregnancy Association (APA). Nightfood is now being formally recommended by the APA to over 3,000,000 pregnant moms as a healthier option for ever-present pregnancy cravings.Folkson reminded investors that Nightfood, at its core, is still focused on the $50 billion dollar nighttime snacking...

Completed dosing of all patients in second cohort of AXO-Lenti-PD dose escalation studyAt present, Company remains on track to achieve key 2020 milestonesNEW YORK and BASEL, Switzerland, April 08, 2020 (GLOBE NEWSWIRE) — Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, today provides a business and operations update during the COVID-19 pandemic.The Company has implemented a business continuity plan to protect the safety of the employees and patients and to mitigate risks of disruption to its clinical programs. At this time, the Company remains on track to achieve its 2020 R&D milestones. Axovant is closely monitoring the coronavirus pandemic and will provide additional updates as appropriate.“Through these unprecedented times, we are committed...

JACKSONVILLE, Fla., April 08, 2020 (GLOBE NEWSWIRE) — Landstar System, Inc. (NASDAQ:LSTR), a worldwide, asset-light provider of integrated transportation management solutions delivering safe, specialized transportation services, announced today it will release its 2020 first quarter results after the market closes on Wednesday, April 22, 2020. The Company will hold its quarterly conference call with analysts and investors the following morning, Thursday, April 23, 2020 at 8:00 a.m. ET to discuss the first quarter results and current outlook. To access the webcast, visit www.investor.landstar.com; click on “Webcasts”; and then “Landstar’s First Quarter 2020 Earnings Release Conference Call.”For those unable to participate in the live call, or for those who do not have access to the Internet, the call...

Correction: corrected technical mistake in Annex No 3 indicating the correct amount of authorized capital.Correction: the record day, which entitles shareholders of the Company by excercising rights of priority to acquire newly issued shares of the Company shall be 27 April 2020

Patikslinimas: ištaisyta techninė klaida priede Nr. 3 nurodant teisingą įstatinio kapitalo dydį.Patikslinimas: teisių apskaitos diena, suteikianti teisę Bendrovės akcininkams pasinaudojant pirmumo teise įsigyti Bendrovės naujai išleidžiamų akcijų – 2020 m. balandžio 27 d. Pranešame, kad AB „Klaipėdos nafta“, juridinio asmens kodas 110648893, buveinė registruota adresu Burių g. 19, Klaipėda (toliau – Bendrovė), valdybos iniciatyva ir sprendimu 2020 m. balandžio 10 d. 13:00 val. sušaukiamas Bendrovės neeilinis visuotinis akcininkų susirinkimas. Susirinkimas vyks Bendrovės buveinėje, adresu: Burių 19, Klaipėda, Bendrovės administracijos patalpose (II aukšto posėdžių salėje).Susirinkimo darbotvarkė:Dėl įstatinio kapitalo didinimo papildomu įnašu;Dėl AB „Klaipėdos nafta“ įstatų keitimo;Dėl AB „Klaipėdos nafta“ įstatinio kapitalo mažinimo;Dėl...

RESEARCH TRIANGLE PARK, N.C., April 08, 2020 (GLOBE NEWSWIRE) — Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products utilizing its proprietary PRINT® technology, today announced that the U.S. Food and Drug Administration (FDA) accepted for review the Company’s New Drug Application (NDA) seeking marketing approval for LIQ861 for the treatment of pulmonary arterial hypertension (PAH). Under the Prescription Drug User Fee Act (PDUFA), the FDA has set a goal date of November 24, 2020. LIQ861 is an investigational, inhaled dry powder formulation of treprostinil designed using the Company’s novel PRINT technology and engineered with the goal of enhancing deep-lung delivery of treprostinil in PAH patients by means of a convenient,...

AUSTIN, Texas, April 08, 2020 (GLOBE NEWSWIRE) — Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as solutions for diseases with high unmet medical need, today announced the approval of its Clinical Trial Application (CTA) by the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) for ACN00177, a novel engineered human enzyme therapy designed to treat Homocystinuria, a serious metabolic disorder characterized by elevated plasma homocysteine levels, leading to a wide range of life-altering complications and reduced life expectancy.“The approval of the CTA for ACN00177 is an important step forward for our Homocystinuria program and for patients who are in need of new treatment options. Given these unprecedented times, our...

BUENA, N.J., April 08, 2020 (GLOBE NEWSWIRE) — Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the fourth quarter and year ended December 31, 2019.Fourth Quarter 2019 HighlightsNet Revenues for the quarter decreased by 5% to $16.0 million compared to the same quarter in 2018, driven primarily by a decline in both U.S. contract manufacturing and international injectable revenues partially offset by a 24% increase in U.S. Teligent label topical revenues $3.0 million of product development and research expenses in the fourth quarter of 2019, a 16% decline compared to $3.6 million for the same quarter in 2018 Selling, general and administrative expenses decreased by 9% to $5.1 million in the fourth quarter of 2019, excluding a $1.9 million non-cash...